Home › Modalities › Peptide
Peptide (19 companies)
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AKTS | Aktis Oncology | Oncology | 8 | Phase 1 | $880M | 10 |
| ALT | Altimmune | GI/HepatologyMetabolic+1 | 3 | Phase 3 | $405M | 3 |
| AMLX | Amylyx Pharmaceuticals | MetabolicNeurology Rare | 3 | Phase 3 | $3.79B | 5 |
| BCYC | Bicycle Therapeutics | Oncology | 3 | Phase 2 | $253M | 4 |
| ELTX | Elicio Therapeutics | Oncology | 5 | Phase 2 | $42.7M | 6 |
| ENTX | Entera Bio | GI/HepatologyMetabolic Rare | 4 | Phase 2 | $547M | 4 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 1 | Approved | $1.63B | 17 |
| GLSI | Greenwich LifeSciences | Oncology | 1 | Phase 3 | $223M | 1 |
| KAPA | Kairos Pharma | Oncology | 1 | Phase 2 | — | 13 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 4 | Phase 2 | $82.0M | 13 |
| NGEN | NervGen Pharma | Neurology | 2 | Phase 3 | $143M | 3 |
| PTN | Palatin Technologies | ImmunologyMetabolic+1 Rare | 4 | Phase 3 | $11.2M | 8 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 10 | Approved | $8.62B | 12 |
| RNTX | Rein Therapeutics | Respiratory Rare | 1 | Phase 2 | $53.0M | 1 |
| RYTM | Rhythm Pharmaceuticals | Metabolic Rare | 12 | Approved | $7.78B | 14 |
| SLS | SELLAS Life Sciences Group | Oncology | 5 | Phase 3 | $1.70B | 9 |
| VRCA | Verrica Pharmaceuticals | DermatologyOncology | 1 | Approved | $54.8M | 3 |
| VKTX | Viking Therapeutics | MetabolicNeurology Rare | 4 | Phase 3 | $3.42B | 9 |
| XERS | Xeris Biopharma | MetabolicNeurology Rare | 1 | Approved | $2.78B | 4 |
No companies match.